American healthcare company WellRX has announced the acquisition of Bioreach, a Utah, US-based laboratory specialising in advanced bloodwork and genetic testing.
The terms of the deal were not disclosed.
WellRX is the parent company of ReviveRX and Ways2Well, which are both preventative healthcare brands.
The acquisition of Bioreach will enable WellRX to bring diagnostic capabilities in-house, enhancing its ability to offer innovative health tests across its ecosystem.
It supports a range of services, including telehealth clinics, weight-loss programmes, testosterone therapies, and regenerative medicine. This is said to align with WellRX’s goal to deliver integrated healthcare solutions focused on optimising patient wellness.
Bioreach’s inclusion is expected to bolster clinic operations by providing data-driven health insights that improve patient outcomes.
Telehealth providers partnered with ReviveRX for prescription services will gain access to streamlined bloodwork integration. According to WellRX, this advancement will support a more cohesive approach to patient care.
The acquisition also expands Ways2Well’s testing services, furthering its preventative care and functional medicine offerings to more than 50,000 patients across the US.
While traditional bloodwork results typically require five to seven business days, Bioreach’s advanced systems are claimed to achieve an 80% improvement in testing efficiency, reducing processing time to just one day.
Bioreach’s laboratory facilities will also support the diagnostic needs of WellRX’s subsidiaries and partners, enabling ReviveRX to deliver personalised prescriptions informed by robust diagnostic data. This capability aligns with ReviveRX’s mission to provide tailored healthcare solutions.
Furthermore, Bioreach’s integration allows WellRX to introduce additional cutting-edge tests, reinforcing its commitment to advancing patient care and driving innovation in preventative healthcare.
WellRX founder and CEO Brigham Buhler said: “By integrating Bioreach’s cutting-edge capabilities, we’re not only accelerating bloodwork turnaround times but also unlocking deeper insights into patient health through our pharmacy and telehealth partnerships.
“This acquisition empowers us to drive down costs, achieve seamless vertical integration, and deliver proactive, predictive care. Together, we are reshaping healthcare to focus on healthspan—and one day, even lifespan—offering unmatched innovation, efficiency, and value to patients, clinicians, and providers.”
